Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Journal of Cancer Research and Treatment. 2014, 2(1), 16-18
DOI: 10.12691/jcrt-2-1-4
Open AccessReview Article

Murine Models of Cancer

Ahmed M Kabel1, and Maaly A Abd Elmaaboud1

1Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt

Pub. Date: February 21, 2014

Cite this paper:
Ahmed M Kabel and Maaly A Abd Elmaaboud. Murine Models of Cancer. Journal of Cancer Research and Treatment. 2014; 2(1):16-18. doi: 10.12691/jcrt-2-1-4


Cancer is a class of diseases in which a group of cells displays uncontrolled growth and invasion that destroys adjacent tissues, and sometimes send metastasis to other locations in the body. When one is interested in cancer research, mice will be the preferred animal. Murine models of cancer include transplantable models, spontaneous and autochthonous models, human tumor xenografts, orthotopic models, models of metastasis and transgenic tumor models.

mice models cancer

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Rick Durrett. Cancer Modeling: A Personal Perspective. Notices of the AMS 2013; 60 (3): 304-309.
[2]  McConville P, Elliott WL, Kreger A, Lister R, Moody JB, Trachet E, Urban F, Leopold WR. Preclinical Models of Tumor Growth and Response. In: Cancer Drug Discovery and Development In Vivo Imaging of Cancer Therapy. Eds: Shields AF and Price P. Humana Press Inc., Totowa, NJ, 2006, pp. 13-32.
[3]  Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer. World J Gastroenterol 2012; 18(12): 1286-1294.
[4]  Cespedes MV, Casanova I, Parrefio M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006; 8(5): 318-329.
[5]  Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer. Am J Pathol 2007; 170(3): 793-804.
[6]  Dykes D, Waud W. Murine L1210 and P388 leukemias. In: Teicher B, ed. Tumor Models in Cancer Research. Totowa, NJ: Humana Press, Inc., 2002, pp. 23-40.
[7]  Zee-Cheng RK, Cheng CC. Screening and evaluation of anticancer agents. Methods Find Exp Clin Pharmacol 1988; 10(2): 67-101.
[8]  Ozaslan M, Karagoz ID, Kilic IH, Guldur ME. Ehrlich ascites carcinoma. Afr J Biotechnol 2011; 10(13): 2375-2378.
[9]  Kabel AM, Abdel-Rahman MN, El-Sisi Ael-D, Haleem MS, Ezzat NM, El Rashidy MA. Effect of atorvastatin and methotrexate on solid Ehrlich tumor. Eur J Pharmacol 2013; 713(1-3):47-53.
[10]  Miranda-Vilelaa AL, Portilhoa FA, de Araujoa V, Estevanatoa L, Mezzomoa B, Santosb M, Lacavaa Z. The protective effects of nutritional antioxidant therapy on Ehrlich solid tumorbearing mice depend on the type of antioxidant therapy chosen: histology, genotoxicity and hematology evaluations. J Nutr Biochem 2011; 22(11):1091-1098.
[11]  Segura JA, Ruiz-Bellido MA, Arenas M, Lobo C, Marquez J, Alonso FJ. Ehrlich Ascites Tumor Cells Expressing Anti-Sense Glutaminase RNA Lose Their Capacity to Evade the Mouse Immune System. Int J Cancer 2001; 91: 379-384.
[12]  Nakagama H, Ochiai M, Ubagai T, et al. A rat colon cancer model induced by 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine, PhIP. Mutat Res 2002; 506-507:137-144.
[13]  Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches. Clin Cancer Res 2005; 11(3): 971-981.
[14]  Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA. The hollow fibre model in cancer drug screening: The NCI experience. Eur J Cancer 2004; 40(6): 821-826.
[15]  Fidler IJ. The pathogenesis of cancer metastasis: The seed and soil hypothesis revisited. Nat Rev Cancer 2003; 3(6): 453-458.
[16]  Lowy AM. Transgenic models of pancreatic cancer. Int J Gastrointest Cancer 2003; 33(1): 71-78.
[17]  Kasper S, Smith JA. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 2004; 172(1): 12-19.